Skip to main content
. 2021 Mar 18;106(9):2364–2373. doi: 10.3324/haematol.2020.272500

Figure 3.

Figure 3.

Duration of response to acalabrutinib. (A, B) The median duration of response was not reached when patients with partial remission with lymphocytosis were excluded (A) or when they were included (B). CI: confidence interval; DOR: duration of response; PR: partial remission; PRL: partial remission with lymphocytosis.